Meeting
2018 ASCO Annual Meeting
First-in-human phase 1 study of DS-1062a in patients (pts) with advanced solid tumors (AST).
Authors
Jacob M. Sands
Dana-Farber Cancer Institute, Boston, MA
Jacob M. Sands , Toshio Shimizu , Edward B. Garon , Jonathan Greenberg , Rebecca Suk Heist , Fumiaki Kobayashi , Yutaka Noguchi , Daisuke Okajima , Alexander I. Spira , Noboru Yamamoto , Tomonari Yamashita , Aaron Elliott Lisberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Immunoconjugates
Clinical Trial Registration Number
NCT03401385
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS2605)
DOI
10.1200/JCO.2018.36.15_suppl.TPS2605
Abstract #
TPS2605
Poster Bd #
426b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.
First Author: Jacob M. Sands
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu
Poster
2023 ASCO Annual Meeting
Sudocetaxel zendusortide (TH1902), a novel sortilin-receptor (SORT1)-targeting peptide-drug-conjugate (PDC) in patients (pts) with advanced solid tumors: Results from part 1 (dose-escalation) of a phase 1, open-label study.
First Author: Funda Meric-Bernstam